Celldex Therapeutics (NASDAQ:CLDX) and Senti Biosciences (NASDAQ:SNTI) Head-To-Head Survey

Senti Biosciences (NASDAQ:SNTI) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Senti Biosciences and Celldex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Insider & Institutional Ownership

25.7% of Senti Biosciences shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Senti Biosciences and Celldex Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1	0	2	1	2.75
Celldex Therapeutics	1	1	11	1	2.86

Senti Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 2,995.98%. Celldex Therapeutics has a consensus target price of $61.92, suggesting a potential upside of 93.99%. Given Senti Biosciences’ higher possible upside, research analysts clearly believe Senti Biosciences is more favorable than Celldex Therapeutics.

Volatility and Risk

Senti Biosciences has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Valuation & Earnings

This table compares Senti Biosciences and Celldex Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20,000.00	503.07	-$61.44 million	($1.77)	-0.18
Celldex Therapeutics	$1.54 million	1,627.71	-$258.76 million	($4.35)	-7.34

Senti Biosciences has higher earnings, but lower revenue than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Celldex Therapeutics beats Senti Biosciences on 7 of the 13 factors compared between the two stocks.

About Senti Biosciences

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.